http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H0753380-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c6191997ed6dda6a5a3582e10b0b3dbc |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D239-60 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-06 |
| filingDate | 1993-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0b9c0882d3c3993ec7a305e5189b5f9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d80155803c282d453dd220aed3621cab http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_40f28d9c17bfcb057891c2bf3f9b770a |
| publicationDate | 1995-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | JP-H0753380-A |
| titleOfInvention | Hyperlipidemia treatment agent and hyperuricemia treatment agent |
| abstract | (57) [Summary] [Structure] A therapeutic agent for hyperlipidemia and hyperuricemia comprising a pyrimidine derivative represented by the general formula (I) or a pharmacologically acceptable salt thereof as an active ingredient. [Chemical 1] (In the formula, R 1 and R 2 are each independently a hydrogen atom, a linear or branched lower alkyl group, a substituted or unsubstituted phenyl group or a cyclohexyl group, and R 3 is a linear or branched chain. Each represents a chain-like lower alkyl group or a lower alkoxy group. In addition, ~ indicates that it includes stereoisomerism.) [Effect] LDL, VLDL, free cholesterol, total cholesterol, and phospholipid levels in blood are significantly increased. HDL while reducing and preventing the oxidation of LDL It is useful in the treatment of hyperlipidemia by increasing the blood concentration of. or, It is also useful for treating hyperuricemia by promoting excretion of uric acid contained in blood, reducing blood concentration of uric acid. Furthermore, the drug has no side effect of causing ulcer of digestive system and is suitable for long-term or repeated continuous oral administration. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107158002-A |
| priorityDate | 1993-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 90.